Shaping the future of pharma
Email: info@amarintech.com.ar
Dermocosmetic patches are not a recent invention. More than 3,000 years ago, Chinese and Egyptian cultures were already applying pharmaceutical preparations to the skin for therapeutic purposes. What is recent is the sophistication of the format: today, that same transdermal delivery logic is applied to cosmetic actives with technical precision [...]
Interchangeability guidances for transdermal systems need harmonization, as the next challenge to add uniformity and scientifical sense to the regulatory process. There are key differences among current guidances for interchangeability of transdermal systems, which could mean that a same clinical study is approved in one region and rejected in another one. [...]
Transdermal patches have come a long way since their introduction in 1979. However, unlike other pharmaceutical forms, they never achieved massive market penetration: between 2015 and 2022, the FDA approved only 84 transdermal patches out of a total of 7,239 generic products, representing just 1.2% of the total. The reason [...]